References
- 1. M. Kansara, M. W. Teng, M. J. Smyth and D. M. Thomas, Translational biology of osteosarcoma, Nat. Rev. Cancer. 14(11) (2014) 722–735; https://doi.org/10.1038/nrc3838
- 2. J. M. Jimenez-Andrade, W. G. Mantyh, A. P. Bloom, A. S. Ferng, C. P. Geffre and P. W. Mantyh, Bone cancer pain, Ann. N. Y. Acad. Sci. 1198 (2010) 173–181; https://doi.org/10.1111/j.1749-6632.2009.05429.x
- 3. Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann. Oncol. 23(7) (2014) 113–123; https://doi.org/10.1093/annonc/mdu256
- 4. L. Wang and G. B. Xue, Catalpol suppresses osteosarcoma cell proliferation through blocking epithelial-mesenchymal transition (EMT) and inducing apoptosis, Biochem Biophys. Res. Commun. 495(1) (2018) 27–34; https://doi.org/10.1016/j.bbrc.2017.10.054
- 5. S. A. Desai, A. Manjappa and P. Khulbe, Drug delivery nanocarriers and recent advances ventured to improve therapeutic efficacy against osteosarcoma: an overview, J. Egypt Natl. Canc. Inst. 33(1) (2021) Article ID 4 (14 pages); https://doi.org/10.1186/s43046-021-00059-3
- 6. I. McCarthy, The physiology of bone blood flow: a review, J. Bone Joint Surg. Am. 88(3) (2006) 4–9; https://doi.org/10.2106/JBJS.F.00890
- 7. O. D. Sherwood, Relaxin’s physiological roles and other diverse actions, Endocr. Rev. 25(2) (2004) 205–234; https://doi.org/10.1210/er.2003-0013
- 8. X. Wei, Y. Yang, Y. J. Jiang, J. M. Lei, J. W. Guo and H. Xiao, Relaxin ameliorates high glucose-induced cardiomyocyte hypertrophy and apoptosis via the Notch1 pathway, Exp. Ther. Med. 15(1) (2018) 691–698; https://doi.org/10.3892/etm.2017.5448
- 9. T. Thanasupawat, A. Glogowska, S. Nivedita-Krishnan, B. Wilson, T. Klonisch and S. Hombach-Klonisch, Emerging roles for the relaxin/RXFP1 system in cancer therapy, Mol. Cell Endocrinol. 487 (2019) 85–93; https://doi.org/10.1016/j.mce.2019.02.001
- 10. D. Bani, A. Pini and S. K. Yue, Relaxin, insulin and diabetes: an intriguing connection, Curr. Diabetes Rev. 8(5) (2012) 329–335; https://doi.org/10.2174/157339912802083487
- 11. A. A. Waza, Z. Hamid, S. A. Bhat, N. U. D. Shah, M. Bhat and B. Ganai, Relaxin protects cardiomyocytes against hypoxia-induced damage in in-vitro conditions: Involvement of Nrf2/HO-1 signaling pathway, Life Sci. 213 (2018) 25–31; https://doi.org/10.1016/j.lfs.2018.08.059
- 12. A. A. Waza, S. A. Bhat and Z. Hamid, Relaxin: A magical therapy for healthy heart, Int. J. Curr. Pharm. Res. 10 (2018) 1–2; http://doi.org/10.22159/ijcpr.2018v10i1.24405
- 13. S. Bruell, A. Sethi, N. Smith, D. J. Scott, M. A. Hossain, Q. P. Wu, Z. Y. Guo, E. J. Petrie, P. R. Gooley and R. A. D. Bathgate, Distinct activation modes of the Relaxin Family Peptide Receptor 2 in response to insulin-like peptide 3 and relaxin, Sci. Rep. 7(1) (2017) Article ID 3294 (12 pages); https://doi.org/10.1038/s41598-017-03638-4
- 14. Y. Radestock, C. Hoang-Vu and S. Hombach-Klonisch, Relaxin reduces xenograft tumour growth of human MDA-MB-231 breast cancer cells, Breast Cancer Res. 10(4) (2008) Article ID R71 (15 pages); https://doi.org/10.1186/bcr2136
- 15. V. B. Nair, C. S. Samuel, F. Separovic, M. A. Hossain and J. D. Wade, Human relaxin-2: historical perspectives and role in cancer biology, Amino Acids 43(3) (2012) 1131–1140; https://doi.org/10.1007/s00726-012-1375-y
- 16. A. Facciolli, A. Ferlin, L. Gianesello, A. Pepe and C. Foresta, Role of relaxin in human osteoclasto-genesis, Ann. N. Y. Acad. Sci. 1160(1) (2009) 221–225; https://doi.org/10.1111/j.1749-6632.2008.03788.x
- 17. A. Ferlin, A. Pepe, A. Facciolli, L. Gianesello and C. Foresta, Relaxin stimulates osteoclast differentiation and activation, Bone 46(2) (2010) 504–513 https://doi.org/10.1016/j.bone.2009.10.007
- 18. T. G. Chan, E. O’Neill, C. Habjan and B, Cornelissen, Combination strategies to improve targeted radionuclide therapy, J.Nucl. Med. 61(11) (2020) 1544–1552; https://doi.org/10.2967/jnumed.120.248062
- 19. J. Yuan, C. Liu, X. Liu, Y. Wang, D. Kuai, G. Zhang and J. J. Zaknun, Efficacy and safety of 177Lu-EDTMP in bone metastatic pain palliation in breast cancer and hormone refractory prostate cancer: a phase II study, Clin. Nucl. Med. 38(2) (2013) 88–92; https://doi.org/10.1097/RLU.0b013e318279bf4d
- 20. S. Chakraborty, T. Das, S. Banerjee, L. Balogh, P. R. Chaudhari, H. D. Sarma, A. Polyak, D. Mathe, M. Venkatesh, G. Janoki and M. R. Pillai, 177Lu-EDTMP: a viable bone pain palliative in skeletal metastasis, Cancer Biother. Radiopharm. 23(2) (2008) 202–213; https://doi.org/10.1089/cbr.2007.374
- 21. C. Kumar, A. Korde, K.V. Kumari, T. Das and G. Samuel, Cellular toxicity and apoptosis studies in osteocarcinoma cells, a comparison of 177Lu-EDTMP and Lu-EDTMP, Curr. Radiopharm. 6(3) (2013) 146–151; https://doi.org/10.2174/18744710113069990021
- 22. C. Kumar, R. Sharma, K. Vats, M. B Mallia, T. Das, H. Sarma and A. Dash, Comparison of the efficacy of 177Lu-EDTMP, 177Lu-DOTMP and 188Re-HEDP towards bone osteosarcoma: an in vitro study, J. Radioanal. Nucl. Chem. 319(1) (2019) 51–59; https://doi.org/10.1007/s10967-018-6283-5
- 23. A. A. Waza, K. Andrabi and M. Ul Hussain, Adenosine-triphosphate-sensitive K+ channel (Kir6.1): a novel phosphospecific interaction partner of connexin 43 (Cx43), Exp. Cell Res. 318(20) (2012) 2559–2566; https://doi.org/10.1016/j.yexcr.2012.08.004
- 24. S. Elmore, Apoptosis: a review of programmed cell death, Toxicol. Pathol. 35(4) (2007) 495–516; https://doi.org/10.1080/01926230701320337
- 25. K. J. Campbell and S. W. G. Tait, Targeting BCL-2 regulated apoptosis in cancer, Open Biol. 8(5) (2018) Article ID 18000 (11 pages); https://doi.org/10.1098/rsob.180002
- 26. S. Pattingre, A. Tassa, X. Qu, R. Garuti, X. H. Liang, N. Mizushima, M. Packer, M. D. Schneider and B. Levine, Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy, Cell 122(6) (2005) 927–939; https://doi.org/10.1016/j.cell.2005.07.002
- 27. G. V. Chaitanya, A. J. Steven and P. P. Babu, PARP-1 cleavage fragments: signatures of cell-death proteases in neurodegeneration, Cell Commun. Signal. 8 (2010) Article ID 31 (11 pages); https://doi.org/10.1186/1478-811X-8-31
- 28. E. M. Carrington, Y. Zhan, J. L. Brady, J. G. Zhang, R. M. Sutherland, N. S. Anstee, R. L. Schenk, I. B. Vikstrom, R. B. Delconte, D. Segal, N. D. Huntington, P. Bouillet, D. M. Tarlinton, D. C. Huang, A. Strasser, S. Cory, M. J. Herold and A. M. Lew, Anti-apoptotic proteins BCL-2, MCL-1 and A1 summate collectively to maintain survival of immune cell populations both in vitro and in vivo, Cell Death Differ. 24(5) (2017) 878–888; https://doi.org/10.1038/cdd.2017.30
- 29. M. Cargnello and P. P. Roux, Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases, Microbiol. Mol. Biol. Rev. 75(1) (2011) 50–83; https://doi.org/10.1128/MMBR.00031-10
- 30. S. Karunakaran, U. Saeed, M. Mishra, R. K. Valli, S. D. Joshi, D. P. Meka, P. Seth and V. Ravindranath, Selective activation of p38 mitogen-activated protein kinase in dopaminergic neurons of substantia nigra leads to nuclear translocation of p53 in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice, J. Neurosci. 28(47) (2008) 12500–12509; https://doi.org/10.1523/JNEUROSCI.4511-08.2008
- 31. Y. Wang, R. Cui, X. Zhang, Y. Qiao, X. Liu, Y. Chang, Y. Yu, F. Sun and J. Wang, SIRT1 increases YAP- and MKK3-dependent p38 phosphorylation in mouse liver and human hepatocellular carcinoma, Oncotarget 7(10) (2016) 11284–11298; https://doi.org/10.18632/oncotarget.7022
- 32. H. K. Koul, M. Pal and S. Koul, Role of p38 MAP kinase signal transduction in solid tumors, Genes Cancer 4(9–10) (2013) 342–359; https://doi.org/10.1177/1947601913507951
- 33. F. Engin, T. Bertin, O. Ma, M. M. Jiang, L. Wang, R. E. Sutton, L. A. Donehower and B. Lee, Notch signaling contributes to the pathogenesis of human osteosarcomas, Hum. Mol. Genet. 18(8) (2009) 1464–1470; https://doi.org/10.1093/hmg/ddp057
- 34. M. Tanaka, T. Setoguchi, M. Hirotsu, H. Gao, H. Sasaki, Y. Matsunoshita and S. Komiya, Inhibition of Notch pathway prevents osteosarcoma growth by cell cycle regulation, Br. J. Cancer 100(12) (2009) 1957–1965; https://doi.org/10.1038/sj.bjc.6605060
- 35. J. S. Mo, J. H. Yoon, E. J. Ann, J. S. Ahn, H. J. Baek, H. J. Lee, S. H. Kim, Y. D. Kim, M. Y. Kim and H. S. Park, Notch1 modulates oxidative stress induced cell death through suppression of apoptosis signal-regulating kinase 1, Proc. Natl. Acad. Sci. USA 110(17) (2013) 6865–6870; https://doi.org/10.1073/pnas.1209078110
- 36. G. Boccalini, C. Sassoli, L. Formigli, D. Bani and S. Nistri, Relaxin protects cardiac muscle cells from hypoxia/reoxygenation injury: Involvement of the Notch-1 pathway, FASEB J, 29(1) (2015) 239–249; https://doi.org/10.1096/fj.14-254854
- 37. Y. Y. Tan, J. D. Wade, G. W. Tregear and R. J. Summers, Quantitative autoradiographic studies of relaxin binding in rat atria, uterus and cerebral cortex: Characterization and effects of oestrogen treatment, Br. J. Pharmacol. 127(1) (1999) 91–98; https://doi.org/10.1038/sj.bjp.0702517